ZL-1503: A Bispecific Antibody Targeting IL-13 and IL-31Rα Sustains Suppression of Pruritus and Atopic Disease in Non-Human Primates 2305220
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1285 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Linda Liu und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
IL-13 and IL-31 are key mediators in atopic diseases. IL-13 promotes type 2 inflammation and tissue changes, while IL-31 drives pruritus and amplifies local immune responses. Their combined effects worsen disease, highlighting the need for dual-targeted treatments. ZL-1503 is a bispecific antibody with extended half-life that blocks both IL-13 and IL-31Rα signaling.
Methods
In the pruritus model, cynomolgus monkeys (n = 16) received a single IV dose of ZL-1503 (0, 0.3, 3, or 10 mg/kg; n = 4/group). IL-31-mediated scratching and IL-13-induced pSTAT6 were monitored for 112 days. Serum samples were collected for PK analysis. In the atopic disease (asthma/allergic rhinitis) model, cynomolgus monkeys (n = 9; 3/group) were divided into: naive, disease (Ascaris suum challenge), and treatment groups (ZL-1503 10 mg/kg IV + antigen).
Results
In the pruritus model, a dose dependent effect of ZL-1503 was observed in both the magnitude and duration of the response, including inhibition of IL-31-mediated scratching and IL-13-mediated pSTAT6, during a 112-day observation period following ZL-1503 treatment. PK analysis demonstrated a strong PK/PD correlation. In the atopic disease model, ZL-1503 significantly improved airway resistance (RAW, p < 0.001) and dynamic compliance (Cdyn, p < 0.01), and reduced nasal rubbing (p < 0.001) and sneezing frequency (p < 0.0001) compared with disease-induced, untreated animals.
Conclusion
ZL-1503 strongly inhibited IL-13/IL-31 pathways in primates and showed significant effects across atopic conditions in NHP models. These findings support its development for human trials targeting moderate-to-severe atopic dermatitis and other IL-13/IL-31 driven diseases. Funding Source n/a Topic Categories Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
Zitieren
APA
Liu, L., Zhang, L., Wan, B., Ye, Q., Peng, W., Yi, J., Lameh, J., & Charuworn, P. (2026). ZL-1503: A Bispecific Antibody Targeting IL-13 and IL-31Rα Sustains Suppression of Pruritus and Atopic Disease in Non-Human Primates 2305220. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1285
Vancouver
Liu L, Zhang L, Wan B, Ye Q, Peng W, Yi J, et al. ZL-1503: A Bispecific Antibody Targeting IL-13 and IL-31Rα Sustains Suppression of Pruritus and Atopic Disease in Non-Human Primates 2305220. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1285
BibTeX
@article{Liu2026,
author = {Liu, Linda and Zhang, Luyao and Wan, Bing and Ye, Qiuping and Peng, Wilson and Yi, Jiaqing and Lameh, Jelveh and Charuworn, Prista},
title = {ZL-1503: A Bispecific Antibody Targeting IL-13 and IL-31Rα Sustains Suppression of Pruritus and Atopic Disease in Non-Human Primates 2305220},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1285}
}
EUVIMED